Preclinical studies have demonstrated that CD47 blockade induces robust antitumor responses particularly in hematologic malignancies [6, 7], and its therapeutic efficacy is enhanced when combined with tumor-targeting antibodies such as rituximab, which engage activating Fc receptors to deliver pro-phagocytic “eat me” signals [8, 9]. Here, CD47 is linked to neoplasm.